Resmed Inc
ASX: RMD
RMD experiencing a technical correction despite strong fundamentals.
(Source: TradingView) 3-Month Performance Profile of RMD compared to the S&P/ASX 200 (XJO).
In the most recent quarter, ResMed reported an 8% year-over-year increase in revenue, reaching $1.3 billion, with constant currency growth of 9%. Operating cash flow stood at $579 million, reflecting strong financi
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
